| __timestamp | Incyte Corporation | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3004000 | 520990000000 |
| Thursday, January 1, 2015 | 26972000 | 535405000000 |
| Friday, January 1, 2016 | 58187000 | 558755000000 |
| Sunday, January 1, 2017 | 79479000 | 495921000000 |
| Monday, January 1, 2018 | 94123000 | 659690000000 |
| Tuesday, January 1, 2019 | 114249000 | 1089764000000 |
| Wednesday, January 1, 2020 | 131328000 | 994308000000 |
| Friday, January 1, 2021 | 150991000 | 1106846000000 |
| Saturday, January 1, 2022 | 206997000 | 1244072000000 |
| Sunday, January 1, 2023 | 255000000 | 1431505000000 |
| Monday, January 1, 2024 | 312068000 | 1431505000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. This analysis focuses on Takeda Pharmaceutical Company Limited and Incyte Corporation, two prominent players in the field. Over the past decade, Takeda has consistently demonstrated a robust cost of revenue, peaking at approximately 1.43 trillion in 2023, a 174% increase from 2014. In contrast, Incyte Corporation has shown a remarkable growth trajectory, with its cost of revenue surging by over 8,400% from 2014 to 2023, reaching 255 million. This stark contrast highlights Takeda's established market presence and Incyte's rapid expansion. Notably, the data for 2024 is incomplete, indicating potential shifts in the coming year. As these companies navigate the complexities of the pharmaceutical landscape, their financial strategies will be pivotal in shaping their future success.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Incyte Corporation
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs United Therapeutics Corporation
Takeda Pharmaceutical Company Limited and Incyte Corporation: A Detailed Gross Profit Analysis
Analyzing Cost of Revenue: Takeda Pharmaceutical Company Limited and Cytokinetics, Incorporated
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored